Evelo Biosciences Analyst Ratings
Evelo Biosciences Analyst Ratings
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $2.00 to $10.00. The current price Evelo Biosciences (EVLO) is trading at is $7.64, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/26/2023 | 30.98% | Morgan Stanley | $2 → $10 | Maintains | Equal-Weight |
| 02/15/2023 | -73.8% | Morgan Stanley | $4 → $2 | Maintains | Equal-Weight |
| 11/16/2022 | -67.26% | Chardan Capital | → $2.5 | Downgrades | Buy → Neutral |
| 09/09/2022 | -47.61% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/24/2022 | -34.51% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | -34.51% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 443.55% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 57.17% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 397.71% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 266.73% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 70.27% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 135.76% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 83.37% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 253.63% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | -21.41% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 4.78% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 175.05% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | -21.41% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 135.76% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 30.98% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 10/12/2018 | 292.93% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 10/11/2018 | 292.93% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/26/2023 | 30.98% | 摩根士丹利 | 2 美元 → 10 美元 | 維護 | 重量相等 |
| 02/15/2023 | -73.8% | 摩根士丹利 | 4 美元 → 2 美元 | 維護 | 重量相等 |
| 11/16/2022 | -67.26% | 查丹資本 | → 2.5 美元 | 降級 | 買入 → 中性 |
| 09/09/2022 | -47.61% | 摩根士丹利 | 5 美元 → 4 美元 | 維護 | 重量相等 |
| 2022 年 8 月 24 日 | -34.51% | 摩根士丹利 | 6 美元 → 5 美元 | 維護 | 重量相等 |
| 08/15/2022 | -34.51% | 查丹資本 | 12 美元 → 5 美元 | 維護 | 購買 |
| 11/02/2021 | 443.55% | JMP 證券 | 44 美元 → 41.5 美元 | 維護 | 市場表現跑贏大盤 |
| 11/01/2021 | 57.17% | 查丹資本 | → 12 美元 | 升級 | 中性 → 買入 |
| 06/23/2021 | 397.71% | JMP 證券 | 36 美元 → 38 美元 | 維護 | 市場表現跑贏大盤 |
| 06/23/2021 | 266.73% | 坎託·菲茨傑拉德 | → 28 美元 | 啓動覆蓋開啓 | → 超重 |
| 05/03/2021 | 70.27% | 摩根士丹利 | 14 美元 → 13 美元 | 維護 | 重量相等 |
| 2021 年 12 月 4 日 | 135.76% | 傑富瑞 | 11 美元 → 18 美元 | 升級 | 持有 → 買入 |
| 2021 年 1 月 19 日 | 83.37% | 摩根士丹利 | 6 美元 → 14 美元 | 維護 | 重量相等 |
| 2020 年 12 月 23 日 | 253.63% | JMP 證券 | → 27 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 11/11/2020 | -21.41% | 摩根士丹利 | 8 美元 → 6 美元 | 維護 | 重量相等 |
| 05/21/2020 | 4.78% | 摩根士丹利 | → 8 美元 | 降級 | 超重 → 重量相等 |
| 05/12/2020 | 175.05% | BMO 資本 | 24 美元 → 21 美元 | 維護 | 跑贏大盤 |
| 05/12/2020 | -21.41% | 傑富瑞 | 18 美元 → 6 美元 | 降級 | 買入 → 持有 |
| 2019 年 4 月 30 日 | 135.76% | 傑富瑞 | → 18 美元 | 啓動覆蓋開啓 | → 購買 |
| 2019 年 1 月 29 日 | 30.98% | 查丹資本 | → 10 美元 | 啓動覆蓋開啓 | → 中立 |
| 2018 年 12 月 10 日 | 292.93% | 摩根士丹利 | 29 美元 → 30 美元 | 維護 | 超重 |
| 10/11/2018 | 292.93% | 摩根士丹利 | 29 美元 → 30 美元 | 維護 | 超重 |
What is the target price for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的目標價格是多少？
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by Morgan Stanley on July 26, 2023. The analyst firm set a price target for $10.00 expecting EVLO to rise to within 12 months (a possible 30.98% upside). 6 analyst firms have reported ratings in the last year.
摩根士丹利於2023年7月26日公佈了Evelo Biosciences（納斯達克股票代碼：EVLO）的最新目標股價。這家分析公司將目標股價定爲10.00美元，預計EVLO將在12個月內升至10.00美元（可能上漲30.98％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的最新分析師評級是多少？
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by Morgan Stanley, and Evelo Biosciences maintained their equal-weight rating.
Evelo Biosciences（納斯達克股票代碼：EVLO）的最新分析師評級由摩根士丹利提供，Evelo Biosciences維持其同等權重評級。
When is the next analyst rating going to be posted or updated for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on July 26, 2023 so you should expect the next rating to be made available sometime around July 26, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Evelo Biosciences的高管和客戶交談以及聽取財報電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Evelo Biosciences的最後一次評級是在2023年7月26日提交的，因此你應該預計下一個評級將在2024年7月26日左右公佈。
Is the Analyst Rating Evelo Biosciences (EVLO) correct?
分析師對 Evelo Biosciences (EVLO) 的評級正確嗎？
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $2.00 to $10.00. The current price Evelo Biosciences (EVLO) is trading at is $7.64, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Evelo Biosciences（EVLO）評級維持不變，目標股價爲2.00美元至10.00美元。Evelo Biosciences（EVLO）目前的交易價格爲7.64美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。
